<?xml encoding="utf-8" ?????????>Laverock Therapeutics, established to commercialise the gene editing induced gene silencing platform for all human therapeutic applications has announced it has expanded its seed funding round to £13.5M.This investment was led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia